{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:04:48Z","timestamp":1785413088373,"version":"3.56.0"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T00:00:00Z","timestamp":1635379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>In diabetes mellitus, during the last years, cancer became of equivalent importance as a cardiovascular disease in terms of mortality. In an earlier study, we have analyzed data of the National Health Insurance Fund (NHIF) of Hungary with regards all patients treated with sodium-glucose co-transporter 2 (SGLT2) inhibitors (SGLT2is) <jats:italic>vs<\/jats:italic>. those treated with dipeptidyl peptidase-4 (DPP-4) inhibitors (DPP-4is) in a given timeframe. In propensity score-matched groups of SGLT2i- <jats:italic>vs<\/jats:italic>. DPP-4i-treated patients, we found a lower incidence of cancer in general. In this post-hoc analysis, we aimed to obtain data on the incidence of site-specific cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>All patients starting an SGLT2i or a DPP-4i between 2014 and 2017 in Hungary were included; the two groups (SGLT2i <jats:italic>vs<\/jats:italic>. DPP-4i) were matched for 54 clinical and demographical parameters. The follow-up period was 639 <jats:italic>vs<\/jats:italic>. 696 days, respectively. Patients with a letter \u201cC\u201d International Classification of Diseases, 10th Revision (ICD-10) code have been chosen, and those with a known malignancy within a year before the onset of the study have been excluded from the analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We found a lower risk of urinary tract [HR 0.50 (95% CI: 0.32\u20130.79) p = 0.0027] and hematological malignancies [HR 0.50 (95% CI: 0.28\u20130.88) p = 0.0174] in patients treated with SGLT2i <jats:italic>vs<\/jats:italic>. those on DPP-4i. Risk of other types of cancer (including lung and larynx, lower gastrointestinal (GI) tract, rectum, pancreas, non-melanoma skin cancers, breast, or prostate) did not differ significantly between the two groups. When plotting absolute risk difference against follow-up time, an early divergence of curves was found in case of prostate, urinary tract, and hematological malignancies, whereas late divergence can be seen in case of cancers of the lung and larynx, the lower GI tract, and the breast.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Urinary tract and hematological malignancies were less frequent in patients treated with SGLT2i <jats:italic>vs<\/jats:italic>. DPP-4i. An early <jats:italic>vs<\/jats:italic>. late divergence could be observed for different cancer types, which deserves further studies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.725465","type":"journal-article","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T07:09:18Z","timestamp":1635404958000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Sodium-Glucose Co-Transporter 2 Inhibitors May Change the Development of Urinary Tract and Hematological Malignancies as Compared With Dipeptidyl Peptidase-4 Inhibitors: Data of the Post-Hoc Analysis of a Nationwide Study"],"prefix":"10.3389","volume":"11","author":[{"given":"Gy\u00f6rgy","family":"Rokszin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor","family":"S\u00fct\u0151","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Kempler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gy\u00f6rgy","family":"Jermendy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibolya","family":"F\u00e1bi\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Szekanecz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyula","family":"Po\u00f3r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istv\u00e1n","family":"Wittmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerg\u0151 Attila","family":"Moln\u00e1r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-S010","article-title":"Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes 2021","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"B2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"ESC Guidelines on Diabetes, Pre-Diabetes, and Cardiovascular Diseases Developed in Collaboration With the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1007\/s00125-020-05151-2","article-title":"Correction to: 2019 Update to: Management of Hyperglycaemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (Diabetologia, (2020), 63, 2, (221-228), 10.1","volume":"63","author":"Buse","year":"2020","journal-title":"Diabetologia"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30431-9","article-title":"Trends in Predominant Causes of Death in Individuals With and Without Diabetes in England From 2001 to 2018: An Epidemiological Analysis of Linked Primary Care Records","volume":"9","author":"Pearson-Stuttard","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000017461","article-title":"Does Long-Term Use of Antidiabetic Drugs Changes Cancer Risk","volume":"98","author":"Liu","year":"2019","journal-title":"Med (United States)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21239175","article-title":"How Far are We From Prescribing Fasting as Anticancer Medicine","volume":"21","author":"Deligiorgi","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-001765","article-title":"Risk of Morbidity and Mortality in Patients With Type 2 Diabetes Treated With Sodium-Glucose Cotransporter-2 Inhibitor and\/or Dipeptidyl Peptidase-4 Inhibitor: A Nationwide Study","volume":"9","author":"Suto","year":"2021","journal-title":"BMJ Open Diabetes Res Care"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2014.03.006","article-title":"Risk-Difference Curves can be Used to Communicate Time-Dependent Effects of Adjuvant Therapies for Early Stage Cancer","volume":"67","author":"Coory","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2337\/diaspect.27.4.276","article-title":"The Diabetes-Cancer Link","volume":"27","author":"Collins","year":"2014","journal-title":"Diabetes Spectr"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-19-1623","article-title":"Diabetes, Glycated Hemoglobin, and Risk of Cancer in the UK Biobank Study","volume":"29","author":"Peila","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1016\/S2213-8587(18)30150-5","article-title":"Worldwide Burden of Cancer Attributable to Diabetes and High Body-Mass Index: A Comparative Risk Assessment","volume":"6","author":"Pearson-Stuttard","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.5041\/rmmj.10043","article-title":"The Role for Insulin and Insulin-Like Growth Factors in the Increased Risk of Cancer in Diabetes","volume":"2","author":"LeRoith","year":"2011","journal-title":"Rambam Maimonides Med J"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2337\/DC07-0233","article-title":"Dipeptidyl Peptidase-4 Inhibitors","volume":"30","author":"Ahr\u00e9n","year":"2007","journal-title":"Diabetes Care"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1186\/1758-5996-3-10","article-title":"Mechanism of the Mitogenic Influence of Hyperinsulinemia","volume":"3","author":"Draznin","year":"2011","journal-title":"Diabetol Metab Syndr"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13092191","article-title":"Cd26\/dpp-4: Type 2 Diabetes Drug Target With Potential Influence on Cancer Biology","volume":"13","author":"Kawakita","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1158\/1541-7786.MCR-20-0115","article-title":"Metformin Mitigates DPP-4 Inhibitor-Induced Breast Cancer Metastasis via Suppression of mTOR Signaling","volume":"19","author":"Kawakita","year":"2021","journal-title":"Mol Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2278","article-title":"Dipeptidyl Peptidase 4 Inhibitors as Novel Agents in Improving Survival in Diabetic Patients With Colorectal Cancer and Lung Cancer: A Surveillance Epidemiology and Endpoint Research Medicare Study","volume":"8","author":"Bishnoi","year":"2019","journal-title":"Cancer Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00405","article-title":"Impact of DPP4 Inhibitors in Survival of Patients With Prostate, Pancreas, and Breast Cancer","volume":"10","author":"Shah","year":"2020","journal-title":"Front Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S215107","article-title":"Incident Cancer Risk in Dipeptidyl Peptidase-4 Inhibitor-Treated Patients With Type 2 Diabetes Mellitus","volume":"11","author":"Choi","year":"2019","journal-title":"Cancer Manag Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjdrc-2020-001787","article-title":"Long-Term Safety and Efficacy of Alogliptin, a DPP-4 Inhibitor, in Patients With Type 2 Diabetes: A 3-Year Prospective, Controlled, Observational Study (J-BRAND Registry)","volume":"9","author":"Ueki","year":"2021","journal-title":"BMJ Open Diabetes Res Care"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-07921-2","article-title":"Dipeptidyl Peptidase-4 Inhibitors and Cancer Risk in Patients With Type 2 Diabetes: A Meta-Analysis of Randomized Clinical Trials","volume":"7","author":"Zhao","year":"2017","journal-title":"Sci Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-020-01479-8","article-title":"Risk of Cancer in Patients Treated With Dipeptidyl Peptidase-4 Inhibitors: An Extensive Meta-Analysis of Randomized Controlled Trials","volume":"57","author":"Dicembrini","year":"2020","journal-title":"Acta Diabetol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2018.1766","article-title":"A Multi\u2212Center Retrospective Analysis of the Effect of DPP4 Inhibitors on Progression\u2212Free Survival in Advanced Airway and Colorectal Cancers","volume":"10","author":"Ali","year":"2018","journal-title":"Mol Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2478\/aiht-2018-69-3204","article-title":"Sodium-Glucose Cotransporters: New Targets of Cancer Therapy","volume":"69","author":"Maduni\u0107","year":"2018","journal-title":"Arh Hig Rada Toksikol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00424-020-02448-4","article-title":"SGLT2 and Cancer","volume":"472","author":"Wright","year":"2020","journal-title":"Pfl\u00fcgers Arch - Eur J Physiol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13745","article-title":"Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors and Cancer: A Meta-Analysis of Randomized Controlled Trials","volume":"21","author":"Dicembrini","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab094","article-title":"Effects of Dapagliflozin on Mortality in Patients With Chronic Kidney Disease: A Pre-Specified Analysis From the DAPA-CKD Randomized Controlled Trial","volume":"42","author":"Heerspink","year":"2021","journal-title":"Eur Heart J"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-015-0128-9","article-title":"Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: The Dapagliflozin Drug Development Program as a \u2018Case Study\u2019","volume":"6","author":"Ptaszynska","year":"2015","journal-title":"Diabetes Ther"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-017-4370-8","article-title":"SGLT2 Inhibitors and Risk of Cancer in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomised Controlled Trials","volume":"60","author":"Tang","year":"2017","journal-title":"Diabetologia"},{"key":"B30","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1080\/00325481.2018.1394152","article-title":"SGLT2 Inhibitors: Are They Safe","volume":"130","author":"Filippas-Ntekouan","year":"2018","journal-title":"Postgrad Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s13300-010-0006-4","article-title":"Quantitative PCR Tissue Expression Profiling of the Human SGLT2 Gene and Related Family Members","volume":"1","author":"Chen","year":"2010","journal-title":"Diabetes Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1126\/science.1260419","article-title":"Tissue-Based Map of the Human Proteome","volume":"347","author":"Uhl\u00e9n","year":"2015","journal-title":"Sci (80-)"},{"key":"B33","unstructured":"Tissue Expression of SLC5A2 - Summary - The Human Protein Atlas"},{"key":"B34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41598-019-54695-w","article-title":"DPP8 is a Novel Therapeutic Target for Multiple Myeloma","volume":"9","author":"Sato","year":"2019","journal-title":"Sci Rep"},{"key":"B35","first-page":"263","article-title":"Introduction To Survival","author":"Silva","year":"","journal-title":"Cancer Epidemiology: Principles and Methods"},{"key":"B36","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/bmj.j2250","article-title":"Life Expectancy Difference and Life Expectancy Ratio: Two Measures of Treatment Effects in Randomised Trials With non-Proportional Hazards","volume":"357","author":"Dehbi","year":"2017","journal-title":"BMJ"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1458-y","article-title":"Late Divergence of Survival Curves in Cancer Immunotherapy Trials: Interpretation and Implications","volume":"62","author":"Thor\u00e9n","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyv200","article-title":"Commentary: The Nature of Cancer Research","volume":"45","author":"Frank","year":"2016","journal-title":"Int J Epidemiol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.623989","article-title":"Dietary Intervention Impacts Immune Cell Functions and Dynamics by Inducing Metabolic Rewiring","volume":"11","author":"Okawa","year":"2021","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1053\/j.seminoncol.2017.10.004","article-title":"Metabolic Coupling and the Reverse Warburg Effect in Cancer: Implications for Novel Biomarker and Anticancer Agent Development","volume":"44","author":"Wilde","year":"2017","journal-title":"Semin Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2020.04.016","article-title":"Mechanisms Leading to Differential Hypoxia-Inducible Factor Signaling in the Diabetic Kidney: Modulation by SGLT2 Inhibitors and Hypoxia Mimetics","volume":"77","author":"Packer","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-51343-1","article-title":"Hypoxia-Inducible Factor-1\u03b1 is the Therapeutic Target of the SGLT2 Inhibitor for Diabetic Nephropathy","volume":"9","author":"Bessho","year":"2019","journal-title":"Sci Rep"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S243170","article-title":"Empagliflozin Protects Against Proximal Renal Tubular Cell Injury Induced by High Glucose via Regulation of Hypoxia-Inducible Factor 1-Alpha","volume":"13","author":"Ndibalema","year":"2020","journal-title":"Diabetes Metab Syndr Obes Targets Ther"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.129034","article-title":"Renal Protective Effects of Empagliflozin via Inhibition of EMT and Aberrant Glycolysis in Proximal Tubules","volume":"5","author":"Li","year":"2020","journal-title":"JCI Insight"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.725465\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T07:09:23Z","timestamp":1635404963000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.725465\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,28]]},"references-count":44,"alternative-id":["10.3389\/fonc.2021.725465"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.725465","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,28]]},"article-number":"725465"}}